Retour

Kyowa Kirin Co., Ltd.

Qualité des données : 100%

Survendu

KYKOF

OTC Healthcare Drug Manufacturers - General

12,42 €

0,00 € (0,00%)

Cap. Boursière : 6,50B

Fourchette du Jour

12,42 € 12,84 €

Fourchette 52 Semaines

12,42 € 18,00 €

Volume

Moyenne 50J / 200J

15,17 € / 15,98 €

Clôture Précédente

12,42 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique	Action	Médiane du Secteur
P/E	0,1	0,4
P/B	0,0	2,9
ROE %	7,7	3,7
Net Margin %	13,5	3,9
Rev Growth 5Y %	9,0	10,0
D/E	0,0	0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2030	158,56 € 154,18 € – 163,82 €	590 B	1
FY2029	170,95 € 166,23 € – 176,62 €	590 B	1
FY2028	153,16 € 148,94 € – 158,24 €	540 B	2

Points Clés

Revenue grew 9,00% annually over 5 years — modest growth

Debt/Equity of 0,00 — conservative balance sheet

Generating 58,96B in free cash flow

P/E of 0,10 — trading at a low valuation

Revenue growth is decelerating — 1Y growth trails 5Y average by 8,66%

Cash machine — converts 87,86% of earnings into free cash flow

Croissance

Revenue Growth (5Y)

9,00%

Revenue (1Y)0,34%

Earnings (1Y)12,07%

FCF Growth (3Y)-15,57%

Qualité

Return on Equity

7,69%

ROIC8,59%

Net Margin13,49%

Op. Margin20,59%

Sécurité

Debt / Equity

0,00

Current Ratio2,72

Interest Coverage28,07

Valorisation

P/E Ratio

0,10

P/B Ratio0,01

EV/EBITDA-2,08

Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	0,34%	Revenue Growth (3Y)	6,04%
Earnings Growth (1Y)	12,07%	Earnings Growth (3Y)	-9,09%
Revenue Growth (5Y)	9,00%	Earnings Growth (5Y)	6,40%
Profitability
Revenue (TTM)	497,26B	Net Income (TTM)	67,10B
ROE	7,69%	ROA	6,05%
Gross Margin	74,25%	Operating Margin	20,59%
Net Margin	13,49%	Free Cash Flow (TTM)	58,96B
ROIC	8,59%	FCF Growth (3Y)	-15,57%
Safety
Debt / Equity	0,00	Current Ratio	2,72
Interest Coverage	28,07	Dividend Yield	0,02%
Valuation
P/E Ratio	0,10	P/B Ratio	0,01
P/S Ratio	0,01	PEG Ratio	1,45
EV/EBITDA	-2,08	Dividend Yield	0,02%
Market Cap	6,50B	Enterprise Value	-212,46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	497,26B	495,56B	442,23B	398,37B	352,25B
Net Income	67,10B	59,87B	81,19B	53,57B	52,35B
EPS (Diluted)	128,18	113,06	151,01	99,66	97,39
Gross Profit	369,21B	362,95B	331,03B	311,46B	264,40B
Operating Income	102,36B	91,87B	86,44B	82,37B	61,17B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	1,11T	1,07T	1,03T	939,88B	921,87B
Total Liabilities	214,72B	216,55B	189,52B	177,06B	184,71B
Shareholders' Equity	894,11B	850,81B	836,42B	762,83B	737,16B
Total Debt	0,0	0,0	19,30B	21,64B	22,54B
Cash & Equivalents	218,96B	244,68B	403,08B	339,19B	335,08B
Current Assets	493,78B	504,03B	611,12B	542,19B	518,23B
Current Liabilities	181,24B	164,68B	133,24B	109,83B	109,13B

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Deep Value Investing (Seth Klarman)

#587 of 820

Value Defensive Investing (Benjamin Graham)

#687 of 708

Activité Récente

Entré Deep Value Investing (Seth Klarman)

Mar 24, 2026

Entré Defensive Investing (Benjamin Graham)

Mar 24, 2026